Expression of HMGB1 and NF-?B p65 and its significance in non-small cell lung cancer

Wspolczesna Onkologia

Volumn 17, Issue 4, 2013, Pages 350-355

  Zhang, Xiaohong ^a   Wang, Hongmin ^b   Wang, Jing ^b  

^a Central Hospital of Zhengzhou   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

High mobility group protein B1; Im mu nohistochemistry; Non small cell lung cancer; Nuclear transcription factor p65; Transfer

Indexed keywords

ANTINEOPLASTIC AGENT; HIGH MOBILITY GROUP B1 PROTEIN; TRANSCRIPTION FACTOR RELA;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HOSPITAL PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; THORAX SURGERY; TUMOR DIFFERENTIATION;

EID: 84886072339     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2013.35291     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Whitson BA, Groth SS, Duval SJ, Swanson SJ, Maddaus MA. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg 2008; 86: 2008- 16.
3. Endo C, Sagawa M, Sakurada A, Sato M, Kondo T, Fujimura S. Surgical treatment of stage I non-small cell lung carcinoma. Ann Thorac Cardiovasc Surg 2003; 9: 283-9.
4. Kang R, Tang D, Schapiro NE, et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010; 17: 666-76.
5. Kowalski DM, Krzakowski M, Ramlau R, Jaskiewicz P, JanowiczZebrowska A. Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland. Wspolczesna Onkol 2012; 16: 170-5.
6. Kew RR, Penzo M, Habiel DM, Marcu KB. The IKKa-dependent NF- ?B p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1. J Immunol 2012; 188: 2380-6.
7. Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101: 2652-60. (Pubitemid 36857626)
8. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008; 11: 91-9.
9. Hasegawa N. Effect of high mobility group box 1 (HMGB1) in cultured human periodontal ligament cells. Kokubyo Gakkai Zasshi 2008; 75: 155-61.
10. Wyrobiec G, Rokicki W, Steplewska K, Kasperczyk J, Stepień- Wyrobiec O, Sabat D, Helewski K. Protein p53 in non-small lung carcinomas. Polish J Cardio-Thoracic Surgery 2011; 8: 77-82.
11. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004; 255: 320-31. (Pubitemid 38324549)
12. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-88.
13. Volz HC, Kaya Z, Katus HA, Andrassy M. The role of HMGB1/RAGE in inflammatory cardiomyopathy. Semin Thromb Hemost 2010; 36: 185-94.
14. Huang W, Tang Y, Li L. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 2010; 51: 119-26.
15. Sasahira T, Kirita T, Oue N, et al. High mobility group box-1- inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 2008; 99: 1806-12.
16. Rauvala H, Rouhiainen A. Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim Biophys Acta 2010; 1799: 164-70.
17. Nogueira-Machado JA, Volpe CM, Veloso CA, ChavesMM. HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin Ther Targets 2011; 15: 1023-35.
18. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705-16. (Pubitemid 16020062)
19. Wang C, Fei G, Liu Z, Li Q, Xu Z, Ren T. HMGB1 was a pivotal synergistic effecor for CpG oligonucleotide to enhance the progression of human lung cancer cells. Cancer Biol Ther 2012; 13: 727-36.
20. Ruan Q, Chen YH. Nuclear factor-?B in immunity and inflammation: the Treg and Th17 connection. Adv Exp Med Biol 2012; 946: 207-21.
21. Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 2003; 9: 346-54. (Pubitemid 36109751)
22. Schulze J, Weber K, Baranowsky A, et al. p65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts. Cancer Lett 2012; 317: 106-13.
23. Li D, Beisswenger C, Herr C, et al. Myeloid cell RelA/p65 promotes lung cancer proliferation through Wnt/β-catenin signaling in murine and human tumor cells. Oncogene 2013 Apr 8. doi: 10.1038/onc.2013.75 [Epub ahead of print].
24. Poser I, Golob M, Buettner R, Bosserhoff AK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003; 23: 2991-8. (Pubitemid 36403094)